Valuation
- Market cap
- 933,226,000
- Revenue TTM
- $24,050,000
- Net income TTM
- $-243,330,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -1,011.77%
- Debt to equity
- 0.00
Trading
- Volume
- 2,624,700
- Avg volume
- 2,698,168
- Day's range
- $6.64 – $7.31
- Shares out
- 129,435,000
- Stochastic %K
- 14%
- Beta
- -0.36
- Analysts
- Strong Sell
- Price target
- $31.12
Company profile
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory a...
Show more
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 231 6625
- Website
- https://www.alumis.com
- Address
- 280 East Grand Avenue, South San Francisco, United States
Latest news
No headlines yet.
